Related Experiment Videos

[Pharmacological therapy of chronic heart failure in the elderly]

Gastone Sabbadini1, Andrea Di Lenarda, Marco Metra

  • 1Struttura Complessa di Cardiologia, Dipartimento di Scienze Cliniche, Morfologiche e Tecnologiche, Università degli Studi, Trieste.

Insights

Heart failure treatment has advanced, focusing on neurohormonal mechanisms. Guidelines should adapt for elderly patients, considering comorbidities and underprescribed evidence-based therapies like ACE-inhibitors and beta-blockers.

Area of Science:

  • Cardiology
  • Pharmacology
  • Geriatrics

Context:

  • Heart failure (HF) management has evolved, driven by understanding neurohormonal pathways.
  • Evidence-based HF treatments favorably alter disease progression.
  • Guideline updates are crucial for real-world application, especially in elderly populations.

Purpose:

  • To review current heart failure treatment strategies and their applicability to elderly patients.
  • To highlight challenges in applying evidence-based medicine to older adults with HF.
  • To identify areas for improved diagnosis and management of heart failure in the elderly.

Summary:

  • Neurohormonal antagonism is key in heart failure treatment.
  • Elderly patients present unique challenges: comorbidities, contraindications, and drug interactions.
  • ACE-inhibitors and beta-blockers are underprescribed; gradual titration ensures tolerability in older adults.
  • Diastolic heart failure diagnosis and treatment remain challenging, requiring further research for elderly patients.

Impact:

  • Emphasizes the need to adapt HF guidelines for elderly patients, addressing specific needs and potential risks.
  • Highlights the underutilization of effective therapies like ACE-inhibitors and beta-blockers in this demographic.
  • Calls for urgent development of multidisciplinary management models for the growing HF patient population.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...